Rivastigmine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Traumatic Brain Injury With Persistent Cognitive Deficits

Conditions

Traumatic Brain Injury With Persistent Cognitive Deficits

Trial Timeline

Nov 1, 2002 → Jan 1, 2005

NCT ID

NCT00219245

About Rivastigmine

Rivastigmine is a approved stage product being developed by Novartis for Traumatic Brain Injury With Persistent Cognitive Deficits. The current trial status is completed. This product is registered under clinical trial identifier NCT00219245. Target conditions include Traumatic Brain Injury With Persistent Cognitive Deficits.

What happened to similar drugs?

7 of 16 similar drugs in Traumatic Brain Injury With Persistent Cognitive Deficits were approved

Approved (7) Terminated (5) Active (5)

✅Galcanezumab-GnlmEli LillyApproved

✅Placebo + sertralineJohnson & JohnsonApproved

✅Adjunctive asenapineMerckApproved

✅AlendronateMerckApproved

✅ZiprasidonePfizerApproved

✅AbobotulinumtoxinA + Normal salineIpsenApproved

✅Tramadol + PlaceboBrain BiotechApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00000174	Phase 3	Completed	—	—	Alzheimer Disease
NCT02989402	Approved	Completed	Dec 31, 2018	Dec 8, 2022	Alzheimer's Disease
NCT02063269	Pre-clinical	UNKNOWN	Feb 1, 2014	Jun 1, 2017	Alzheimer's Disease
NCT00104442	Approved	Completed	Oct 1, 2003	Apr 1, 2006	Alzheimer's Disease
NCT00134953	Phase 3	Terminated	Jan 1, 2003	May 1, 2004	Cognitive Symptoms
NCT00171795	Phase 3	Completed	Nov 1, 2002	May 1, 2005	Traumatic Brain Injury
NCT00219245	Approved	Completed	Nov 1, 2002	Jan 1, 2005	Traumatic Brain Injury With Persistent Cognitive Deficits
NCT00130338	Phase 3	Completed	Feb 1, 2002	May 1, 2006	Vascular Dementia
NCT00099216	Phase 3	Completed	Aug 1, 2001	Nov 1, 2005	Vascular Dementia

Competing Products

20 competing products in Traumatic Brain Injury With Persistent Cognitive Deficits

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Celecoxib	Astellas Pharma	Pre-clinical	26
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product	Sun Pharmaceutical	Phase 1	29
Duloxetine hydrochloride	Eli Lilly	Phase 3	36
Galcanezumab-Gnlm	Eli Lilly	Approved	43
SYN117 (nepicastat) + Placebo comparator	Johnson & Johnson	Phase 2	27
Nepicastat + Placebo	Johnson & Johnson	Phase 2	35
JNJ-17299425	Johnson & Johnson	Phase 2	27
Placebo + sertraline	Johnson & Johnson	Approved	35
Quetiapine Fumarate + quetiapine fumarate placebo	AstraZeneca	Phase 3	40
Adjunctive asenapine	Merck	Approved	43
Rizatriptan + Placebo	Merck	Pre-clinical	18
Alendronate	Merck	Approved	39
Iloperidone + Placebo	Novartis	Phase 2	27
AMG 334	Novartis	Phase 2	35
Rivastigmine	Novartis	Phase 3	40
Balovaptan + Placebo	Roche	Phase 2	35
Erenumab	Amgen	Phase 2	35
Growth Hormone	Novo Nordisk	Phase 2	42